Overview A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Status: Active, not recruiting Trial end date: 2022-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence. Phase: Phase 2 Details Lead Sponsor: Taiho Pharmaceutical Co., Ltd.